Reisewarnung wegen Zika-VirenRecurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?Stroke is not equal to stroke. Keep track of the causesPrimary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarizedPRoFESS study presented. Change in secondary preventionASS and dipyridamole combination. A decisive contribution to secondary prevention after strokeMore than six billions Euro costs due to illness days. Migraine therapy countsSecondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?Heartburn without esophagitis. Symptoms more important than the finding?Before polyp removal. To stop or not to stop ASA?Secondary prevention after stroke. Doubled performs betterAfter stroke or TIA. Double protection by second platelet inhibitorMigraine, inflammation, genes. New risk factors for strokeTherapeutic concepts in the treatment of headacheAttack on many vascular fronts. Atherothrombosis trouble seldom comes alonePatients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart diseaseCombination is standard. Dual thrombocyte function inhibition in acute coronary syndromeInterview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?Secondary prevention after ischemic stroke. High risk patients need special protectionPrimary and secondary prevention of stroke. Prevention is better than healingASS plus dipyridamole instead of ASS monotherapy. Risk for second stroke cut in halfFemale, young, healthy. ASS does not protect from myocardial infarctAfter the disappointing ASS primary prevention trial. "Holding back in women"Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]Acute heart attacks. Prognosis can be further improvedAspirin, triptan tablet, nasal spray, injection. Even the most severe migraine capitulatesPost-zoster neuralgia. Local acetylsalicylic acid stops pain for 5 hoursEmergencies in general practice, 16: Transitory ischemic attacks. When suspected ASS and heparin are contraindicated!Recommendations for treatment with nonsteroidal anti-inflammatory drugsWhen L-Dopa preparations, dopamine agonists or opioids? Therapy of restless legs syndromeHormone replacement therapy in peri- and postmenopause. Routine use is not indicatedTwo platelet inhibitors after acute coronary syndrome. Many colleagues are not aware of thisRisk improves effectiveness. Proper administration of platelet aggregation inhibitorsAcetylsalicylic acid for cardiovascular risk patients. Placebo or life safer?Secondary prevention after stroke. 2 platelet inhibitors are better than oneCoxib spares the stomach. This is true also for patients with preventive aspirin administrationNew US guidelines. Myocardial infarct is now treated more aggressivelyPeripheral arterial occlusive disease. Symptoms, basic diagnosis and staged therapy
P1433
Q24261425-49CB132F-BF60-43B3-A296-F0C2DDBF322EQ28165228-A19FF94D-397B-4039-B6BE-47BF5BF32C92Q28165229-620CBF36-926F-4A47-9EB6-E38250627266Q28165230-26C611B1-1C2E-4E1B-A132-225CB7EE1A07Q28165813-EACD5019-198C-4067-9FC9-B56826163CD8Q28165815-FA91F3AC-2A8F-4946-8D68-70A869150075Q28165817-D904CF5B-640F-415A-A9A9-9FB1EE78839BQ28165818-B6C827D9-B594-4262-9728-91323B51C5AFQ28165876-2C3E7981-ED35-43B6-8CE4-7694E2250C80Q28166307-D6C34971-3B26-4150-9E73-B3190C6DFAD4Q28166310-F6CC630F-82DC-4F43-B803-DC20FD7D7533Q28166637-2C58B98A-AFE1-44A8-9FD7-32388616BCDFQ28167244-945548AE-A1F9-4178-A633-27594835C2D2Q28167327-520F26D1-5DA1-4D78-AA48-59A9D8A4C604Q28169113-62C43BCB-EB02-4E55-9F33-6D6753D597E9Q28171206-C6F22E73-4031-4930-9F38-CCCD5BD74E3BQ28171208-105D2C49-A77F-48FD-A356-A20D99986209Q28171209-C043D558-8978-4090-9232-F155682F0DD6Q28171211-77DDB0EE-3F1A-4440-8794-59BFC3AC851AQ28171212-AC4929D6-C0B3-420C-B779-CBFDD47132E8Q28171214-DBA17C5D-85F3-48D6-ADED-A0A097F77D5EQ28171411-9C71A5F9-D97D-4CE7-A7B6-B42129EBFDFCQ28174095-7E656345-679B-4565-95BF-CA878CCC8280Q28174097-768E08A0-D290-410D-878E-B089D0778553Q28176413-4920619D-0503-4A6B-B609-DC06C6055C9AQ28176419-8E539E66-7B8F-463E-9468-DBCF01442527Q28183098-82536922-1FEB-44D6-BE00-FB3FB41A9F93Q28183946-7DB922C0-C579-4C0C-B73C-572FA5F1D527Q28184965-692288FF-C76C-427A-9C02-9E606FC25B0DQ28185570-B3ED3F4D-F76A-40A6-B5D0-F7A696D38F26Q28189624-2C50A73C-759E-412A-90AA-C07974F5A559Q28190209-86377F2A-8A57-403F-9F31-4169949C1D3DQ28192652-997C0C55-A5D0-4093-8E7A-22C100444ED8Q28192993-824FB04F-506C-49A6-91EB-0419A91AAE2FQ28193210-0D991D84-E228-4BCA-B84A-7A7258402406Q28193211-6480B5B1-EED4-492A-BE6D-72E104FAA730Q28193400-0A0FB1B1-8A47-4A74-80BF-244388C07443Q28193419-4C914DD7-3A71-4A77-ABE8-4C14C362FF2DQ28193420-1698C9AA-10F3-4B66-B3AD-8AF1792EE857Q28193470-AFB46851-E0A6-4BCF-9D5B-3D5223107BE8
P1433
description
German-language scientific journal
@en
Wissenschaftliche Fachzeitschrift
@de
periodiek van uitgeverij Springer Medizin
@nl
name
MMW-Fortschritte der Medizin
@de
MMW-Fortschritte der Medizin
@en
ミュンヘン週刊医療
@ja
慕尼黑医学周刊
@zh
慕尼黑医学周刊
@zh-hans
慕尼黑醫學週刊
@zh-hant
type
label
MMW-Fortschritte der Medizin
@de
MMW-Fortschritte der Medizin
@en
ミュンヘン週刊医療
@ja
慕尼黑医学周刊
@zh
慕尼黑医学周刊
@zh-hans
慕尼黑醫學週刊
@zh-hant
altLabel
Münchener Medizinische Wochenschrift
@de
Münchner Medizinische Wochenschrift
@de
prefLabel
MMW-Fortschritte der Medizin
@de
MMW-Fortschritte der Medizin
@en
ミュンヘン週刊医療
@ja
慕尼黑医学周刊
@zh
慕尼黑医学周刊
@zh-hans
慕尼黑醫學週刊
@zh-hant
P1042
P3181
P1042
P1055
P1156
P123
P131
P1476
MMW
@de
P159
P1680
Fortschritte der Medizin
@de
P236
P31
P3181
P407
P495
P571
1999-01-01T00:00:00Z
P5983
P7140
Münchener_Medizinische_Wochenschrift-Fortschritte_der_Medizin